Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
addiction, Albert, alectinib, Alzheimer, antigen, atrial, autonomy, Bain, BionTech, Bourla, Breakthrough, Cerevel, ceritinib, Chairman, chimeric, cloud, consummated, crizotinib, Cynamid, deletion, Democratic, dissolving, divestiture, epilepsy, exon, fibrillation, floating, flu, gBRCAm, House, Ian, influenza, installment, involuntary, lira, managerial, midterm, Mississippi, monetize, parent, Parkinson, pivotal, preclinical, preferred, PsA, Quillivant, rituximab, schizophrenia, simpler, slight, soberano, succeed, suspected, tavaborole, thereof, true, Turkish, unchanged
Removed:
AML, BeneFIX, cohort, communicating, contractually, cotransporter, curatively, CV, diabetic, educating, elimination, endocrine, exist, focusing, glucose, good, inspection, McPherson, Merkel, mild, moderate, neuralgia, neuropathic, neuropathy, obligated, ointment, penetration, ReFacto, Senate, topical, twelve, unresectable
Filing tables
Filing exhibits
- 10-Q Quarterly report
- 10.1 Amendment No 3 to the Pfizer Supplemental Savings Plan
- 15 Accountants' Acknowledgement
- 31.1 Certification by the CEO - Section 302
- 31.2 Certification by the CFO - Section 302
- 32.1 Certification by the CEO - Section 1350
- 32.2 Certification by the CFO - Section 1350
- Download Excel data file
- View Excel data file
Related press release
Associated PFE transcripts
PFE similar filings
Filing view
External links